239 related articles for article (PubMed ID: 24675871)
1. Increased expression of p62/SQSTM1 in prion diseases and its association with pathogenic prion protein.
Homma T; Ishibashi D; Nakagaki T; Satoh K; Sano K; Atarashi R; Nishida N
Sci Rep; 2014 Mar; 4():4504. PubMed ID: 24675871
[TBL] [Abstract][Full Text] [Related]
2. Pathogenic mutations within the hydrophobic domain of the prion protein lead to the formation of protease-sensitive prion species with increased lethality.
Coleman BM; Harrison CF; Guo B; Masters CL; Barnham KJ; Lawson VA; Hill AF
J Virol; 2014 Mar; 88(5):2690-703. PubMed ID: 24352465
[TBL] [Abstract][Full Text] [Related]
3. Comparison of the anti-prion mechanism of four different anti-prion compounds, anti-PrP monoclonal antibody 44B1, pentosan polysulfate, chlorpromazine, and U18666A, in prion-infected mouse neuroblastoma cells.
Yamasaki T; Suzuki A; Hasebe R; Horiuchi M
PLoS One; 2014; 9(9):e106516. PubMed ID: 25181483
[TBL] [Abstract][Full Text] [Related]
4. Ubiquitin-specific protease 14 modulates degradation of cellular prion protein.
Homma T; Ishibashi D; Nakagaki T; Fuse T; Mori T; Satoh K; Atarashi R; Nishida N
Sci Rep; 2015 Jun; 5():11028. PubMed ID: 26061634
[TBL] [Abstract][Full Text] [Related]
5. Disease-related prion protein forms aggresomes in neuronal cells leading to caspase activation and apoptosis.
Kristiansen M; Messenger MJ; Klöhn PC; Brandner S; Wadsworth JD; Collinge J; Tabrizi SJ
J Biol Chem; 2005 Nov; 280(46):38851-61. PubMed ID: 16157591
[TBL] [Abstract][Full Text] [Related]
6. Anti-prion Protein Antibody 6D11 Restores Cellular Proteostasis of Prion Protein Through Disrupting Recycling Propagation of PrP
Pankiewicz JE; Sanchez S; Kirshenbaum K; Kascsak RB; Kascsak RJ; Sadowski MJ
Mol Neurobiol; 2019 Mar; 56(3):2073-2091. PubMed ID: 29987703
[TBL] [Abstract][Full Text] [Related]
7. A brain aggregate model gives new insights into the pathobiology and treatment of prion diseases.
Bajsarowicz K; Ahn M; Ackerman L; Dearmond BN; Carlson G; DeArmond SJ
J Neuropathol Exp Neurol; 2012 May; 71(5):449-66. PubMed ID: 22507918
[TBL] [Abstract][Full Text] [Related]
8. Novel amplification mechanism of prions through disrupting sortilin-mediated trafficking.
Sakaguchi S; Uchiyama K
Prion; 2017 Nov; 11(6):398-404. PubMed ID: 29099278
[TBL] [Abstract][Full Text] [Related]
9. Polo-like kinase 3 (PLK3) mediates the clearance of the accumulated PrP mutants transiently expressed in cultured cells and pathogenic PrP(Sc) in prion infected cell line via protein interaction.
Wang H; Tian C; Fan XY; Chen LN; Lv Y; Sun J; Zhao YJ; Zhang LB; Wang J; Shi Q; Gao C; Chen C; Shao QX; Dong XP
Int J Biochem Cell Biol; 2015 May; 62():24-35. PubMed ID: 25724737
[TBL] [Abstract][Full Text] [Related]
10. Prions amplify through degradation of the VPS10P sorting receptor sortilin.
Uchiyama K; Tomita M; Yano M; Chida J; Hara H; Das NR; Nykjaer A; Sakaguchi S
PLoS Pathog; 2017 Jun; 13(6):e1006470. PubMed ID: 28665987
[TBL] [Abstract][Full Text] [Related]
11. Strain-dependent profile of misfolded prion protein aggregates.
Morales R; Hu PP; Duran-Aniotz C; Moda F; Diaz-Espinoza R; Chen B; Bravo-Alegria J; Makarava N; Baskakov IV; Soto C
Sci Rep; 2016 Feb; 6():20526. PubMed ID: 26877167
[TBL] [Abstract][Full Text] [Related]
12. Overexpression of p62/SQSTM1 promotes the degradations of abnormally accumulated PrP mutants in cytoplasm and relieves the associated cytotoxicities via autophagy-lysosome-dependent way.
Xu Y; Zhang J; Tian C; Ren K; Yan YE; Wang K; Wang H; Chen C; Wang J; Shi Q; Dong XP
Med Microbiol Immunol; 2014 Apr; 203(2):73-84. PubMed ID: 24240628
[TBL] [Abstract][Full Text] [Related]
13. Infectivity-associated PrP(Sc) and disease duration-associated PrP(Sc) of mouse BSE prions.
Miyazawa K; Okada H; Masujin K; Iwamaru Y; Yokoyama T
Prion; 2015; 9(5):394-403. PubMed ID: 26555211
[TBL] [Abstract][Full Text] [Related]
14. Prion protein and metal interaction: physiological and pathological implications.
Singh N; Das D; Singh A; Mohan ML
Curr Issues Mol Biol; 2010; 12(2):99-107. PubMed ID: 19767653
[TBL] [Abstract][Full Text] [Related]
15. Analyses of protease resistance and aggregation state of abnormal prion protein across the spectrum of human prions.
Saverioni D; Notari S; Capellari S; Poggiolini I; Giese A; Kretzschmar HA; Parchi P
J Biol Chem; 2013 Sep; 288(39):27972-85. PubMed ID: 23897825
[TBL] [Abstract][Full Text] [Related]
16. Soluble dimeric prion protein binds PrP(Sc) in vivo and antagonizes prion disease.
Meier P; Genoud N; Prinz M; Maissen M; Rülicke T; Zurbriggen A; Raeber AJ; Aguzzi A
Cell; 2003 Apr; 113(1):49-60. PubMed ID: 12679034
[TBL] [Abstract][Full Text] [Related]
17. Chemically induced accumulation of GAGs delays PrP(Sc) clearance but prolongs prion disease incubation time.
Mayer-Sonnenfeld T; Avrahami D; Friedman-Levi Y; Gabizon R
Cell Mol Neurobiol; 2008 Nov; 28(7):1005-15. PubMed ID: 18350378
[TBL] [Abstract][Full Text] [Related]
18. Flow Cytometric Detection of PrP
Yamasaki T; Suzuki A; Hasebe R; Horiuchi M
J Virol; 2018 Jan; 92(1):. PubMed ID: 29046463
[TBL] [Abstract][Full Text] [Related]
19. Ethanolamine Is a New Anti-Prion Compound.
Uchiyama K; Hara H; Chida J; Pasiana AD; Imamura M; Mori T; Takatsuki H; Atarashi R; Sakaguchi S
Int J Mol Sci; 2021 Oct; 22(21):. PubMed ID: 34769172
[TBL] [Abstract][Full Text] [Related]
20. The Size and Stability of Infectious Prion Aggregates Fluctuate Dynamically during Cellular Uptake and Disaggregation.
Shoup D; Priola SA
Biochemistry; 2021 Feb; 60(5):398-411. PubMed ID: 33497187
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
